Adrenalina Racémica: Usos y Dosis
Cargado por
Maria Jose RecinosAdrenalina Racémica: Usos y Dosis
Cargado por
Maria Jose RecinosCommon questions
Con tecnología de IARacemic epinephrine offers advantages over other treatments such as beta-agonists due to its superior efficacy in reducing the severity of symptoms and decreasing hospitalization rates. It provides a more direct method of managing edema and obstruction in bronchiolitis caused by RSV .
Racemic epinephrine is significantly more effective than beta-agonists in the treatment of bronchiolitis. It leads to a marked reduction in hospitalizations, indicating superior clinical outcomes due to its effective reduction of airway obstruction .
Since its introduction in 1960 for upper airway obstruction, racemic epinephrine has been clinically adopted due to its efficacy demonstrated in a pivotal 1978 study. Over the years, its role in treating croup and bronchiolitis has been solidified by its rapid action and strong outcomes compared to alternative therapies .
Racemic epinephrine stimulates alpha-adrenergic receptors in the subglottic mucosa, causing vasoconstriction which reduces mucosal edema. This mechanism helps alleviate upper airway obstruction .
The introduction of racemic epinephrine in 1960 was significant due to its effectiveness in managing upper airway obstruction. The first randomized placebo-controlled study in 1978 demonstrated its benefit, providing evidence for its inclusion in clinical practice .
The recommended dosing of racemic epinephrine in pediatric patients is stratified by weight: 0.25 ml for those under 20 kg, 0.5 ml for those between 20 and 40 kg, and 0.75 ml for those over 40 kg. This stratified approach ensures that each child receives a therapeutic dose based on their body weight .
Racemic epinephrine is particularly indicated in moderate to severe croup and bronchiolitis. It is preferred in these conditions due to its significant efficacy in reducing hospitalizations compared to beta-agonists, likely due to its powerful action on reducing airway edema .
Racemic epinephrine's pharmacokinetic profile indicates that its effects last 90 to 120 minutes, with peak effects at 60 minutes post-treatment. This duration supports its use in acute settings as the therapeutic effects are transient but significant, allowing for rapid intervention in cases of severe respiratory distress .
Racemic epinephrine contains equal amounts of d and L isomers, but the pharmacological action is primarily due to the L isomer, which is 30 times more active than the d isomer. This composition enhances its effectiveness in causing vasoconstriction and reducing edema .
In clinical practice, racemic epinephrine exhibits a rapid onset, with peak effects at 60 minutes, and a total duration of 90 to 120 minutes. This makes it ideal for emergency protocols where immediate relief is necessary to stabilize patients with acute airway obstruction .
